Compositions, methods and kits for treating complement related disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for complement-related disorders, such as age-related macular degeneration and rheumatoid arthritis, are limited by the availability of effective FDA-approved inhibitors and often require repeated injections with significant side effects, necessitating a more efficient and safer therapeutic approach.
Innovation Solution
A pharmaceutical composition comprising a recombinant chimeric protein with amino acid sequences from CD46, CD55, and CD59 proteins, engineered to modulate classical and alternative complement pathways, is developed, which can be administered via gene therapy using vectors like adeno-associated virus to provide long-term attenuation of complement activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If repeated injections of complement inhibitors are administered to treat chronic disorders, then therapeutic efficacy is improved, but patient convenience deteriorates and side effects increase
Solution Approach 1:
The patent applies preliminary action by using gene therapy to deliver complement inhibitor genes (such as CD59, CD55, or CD46) to target tissues in advance, enabling the body to produce the therapeutic protein locally over an extended period. This single administration establishes long-term protection against complement-mediated damage, eliminating the need for repeated injections while maintaining therapeutic efficacy.
2Reliability
If repeated injections of complement inhibitors are administered, then therapeutic efficacy is improved, but side effects worsen
Solution Approach 1:
The patent uses gene therapy vectors as intermediaries to deliver complement inhibitor genes to target tissues. These vectors mediate the transfer of genetic material that encodes protective proteins (CD59, CD55, or CD46), which then locally regulate complement activation. This intermediary approach allows sustained therapeutic effect while minimizing systemic exposure and associated side effects.
3Adaptability or versatility
If current FDA-approved complement inhibitors are used, then treatment availability is improved, but treatment effectiveness for chronic disorders deteriorates
Solution Approach 1:
The patent applies parameter changes by transitioning from administering pre-formed complement inhibitor proteins to delivering genes that encode these inhibitors. This fundamental parameter change enables local, sustained production of therapeutic proteins at physiological concentrations, providing long-term protection against complement-mediated damage in chronic disorders where current inhibitors have limited effectiveness.
Data Source
AI summary
Compositions, methods and kits are provided for treating complement related disorders in a subject with protein in combination having protein fusions of at least two of a CD46 protein, a CD55 protein and a CD59 protein or with a recombinant chimeric protein having at least two of a CD46 protein, a CD55 protein and a CD59 protein or with nucleic acids encoding these proteins. The composition negatively modulates classical and alternative complement pathways thereby treating complement related disorder such as macular degeneration, age-related macular degeneration, diabetic retinopathy, inflammatory bowel disease, thyroiditis, cryoglobulinaemia, fetal loss, organ graft rejection, cancer, etc.